New Research Confirms the Benefit of Dario's Integrated,
Data-Driven Approach to Health and Chronic Condition
Management
NEW
YORK, Sept. 10, 2024 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market announced today the publication of a
new study in the peer-reviewed journal Frontiers in Endocrinology.
The study demonstrates the effectiveness of Dario's cardiometabolic
solution for members living with diabetes or prediabetes and
depression.
Approximately 18%–25% of people living with type 2 diabetes
(T2D) experience depression1. The co-occurrence of these
conditions can lead to poor health outcomes and increased costs for
employers and payers, driving demand for integrated solutions to
help improve clinical and financial results2,3. Dario's
cardiometabolic solution offers members with T2D and prediabetes
highly individualized journeys to help manage conditions with a
holistic approach that includes integrated mental health support.
Data captured from each member's journey, including clinical data
such as blood glucose (BG) readings and behavioral data from
engagement in digital tools, are integrated in a single,
comprehensive data environment to support continuous
personalization. This approach allows Dario to better understand
the interconnected nature of depression and chronic conditions.
Dario's capability to integrate data through the pedometer of a
smart mobile device or steps being tracked by Apple Health enables
a new way to assess the relationship between depressive symptoms
and blood glucose levels in individuals with T2D over time, with a
particular focus on walking activity as a potential behavioral
mediator.
"This new research shows the importance of providing a holistic
approach to health management. People living with chronic health
needs are often trying to manage multiple needs at once, and we
believe that Dario's focus on driving healthy behaviors is
necessary to improve health and realize better outcomes overall. We
are excited to share this data and add new insights to reinforce
the impact Dario offers to its members and partners," said Yifat
Hershcovitz, PhD., Vice President of Clinical and Scientific
Affairs at Dario.
"Dario is uniquely positioned to help shed light on the
relationship between physical and mental health thanks to the rich
volume of data we are able to gather and analyze for insights that
benefit our members and our partners. This new research exemplifies
the advantages of our data-driven approach to digital health and
supports the value of our integrated approach to help employers and
health plans to tackle costly and frequently co-morbid conditions,"
said Omar Manejwala, M.D., Chief
Medical Officer at Dario.
Improving Outcomes for Members with Co-Occurring
Conditions
The new research used retrospective data from 989 users who
regularly tracked their steps levels and BG levels for 12 months
using Dario's cardiometabolic solution.
This study demonstrates how regular walking can mitigate the
negative impact of depression on blood glucose levels in
individuals with type 2 diabetes or prediabetes, revealing the
following:
- Dario members who reported depression exhibited higher average
BG levels compared to those without depression. In both cases
members experienced a significant decrease in BG levels during the
initial 4 months of platform usage, followed by a stable period
during months 4-12 of the monitoring.
- A statistically significant association was found between the
depression status and BG levels. Also, a statistically
significant association was found between the depression status and
monthly average number of steps.
- The monthly average number of steps fully mediates the
association between self-reported depression and monthly
average BG.
- A significant decrease in monthly average blood glucose for
users with monthly average number of steps a day above 400.
The new study supports the incorporation of walking into
treatment protocols as a cost-effective and accessible intervention
strategy to improve glycemic control and alleviate depressive
symptoms in people living with T2D and depression.
The research was conducted in partnership with Integrative Pain
Laboratory, the School of Public Health at the University of Haifa, Israel.
You can read the full study here.
Refs:
- Darwish L, Beroncal E, Sison MV, Swardfager W. Depression in
people with type 2 diabetes: current perspectives. Diabetes Metab
Syndr Obes. (2018) 11:333–43.
- Fisher E, Chan J, Nan H, Sartorius N, Oldenburg B.
Co-occurrence of diabetes and depression: Conceptual considerations
for an emerging global health challenge. J Affect Disord. (2012)
142 Suppl:S56–66.
- Egede L, Walker R, Bishu K, Dismuke C. Trends in Costs of
Depression in Adults with Diabetes in the
United States: Medical Expenditure Panel Survey, 2004–2011.
J Gen Intern Med, (2016) 31(6): 615-622.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to
do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the effectiveness of Dario's cardiometabolic solution for members
living with diabetes or prediabetes and depression, and its ability
to improve health and tackle costly and frequently co-morbid
conditions. Without limiting the generality of the foregoing,
words such as "plan," "project," "potential," "seek," "may,"
"will," "expect," "believe," "anticipate," "intend," "could,"
"estimate" or "continue" are intended to identify forward-looking
statements. Readers are cautioned that certain important factors
may affect the Company's actual results and could cause such
results to differ materially from any forward-looking statements
that may be made in this news release. Factors that may affect the
Company's results include, but are not limited to, regulatory
approvals, product demand, market acceptance, impact of competitive
products and prices, product development, commercialization or
technological difficulties, the success or failure of negotiations
and trade, legal, social and economic risks, and the risks
associated with the adequacy of existing cash resources. Additional
factors that could cause or contribute to differences between the
Company's actual results and forward-looking statements include,
but are not limited to, those risks discussed in the Company's
filings with the U.S. Securities and Exchange Commission. Readers
are cautioned that actual results (including, without limitation,
the timing for and results of the Company's commercial and
regulatory plans for Dario™ as described herein) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+1-315-378-6922
Logo:
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/dario-publishes-new-research-revealing-how-physical-activity-mediates-the-impact-of-depression-on-blood-glucose-levels-in-individuals-with-diabetes-or-prediabetes-302243570.html
SOURCE DarioHealth Corp.
